Mesa Laboratories (MLAB) Q1 2025 earnings summary

Executive summary

• Revenues for Q1 FY2025 rose 14.9% year-over-year to $58.2M, driven by the GKE acquisition and organic growth in Biopharmaceutical Development and other segments.

• Net income was $3.4M, up from a net loss of $0.5M in the prior year, with diluted EPS of $0.62.

• Operating income increased to $5.6M from a loss of $0.7M, and AOI margin excluding unusual items reached 26.4%.

• Non-GAAP core organic revenues grew 3.0%, with adjusted operating income up 33.9%.

• Debt repayment of $9.4M reduced the Net Leverage Ratio to 3.41, with a target below 3.0x.

Financial highlights

• Gross profit increased 19% to $37.2M, with gross margin up two points to 64% year-over-year.

• AOI margin excluding unusual items reached 26.4% of revenues.

• Operating expenses remained flat despite higher revenues, aided by lower amortization expense.

• Cash and cash equivalents stood at $28.5M at quarter-end.

• Cash from operations was $10.4M, up $0.5M year-over-year.

Outlook and guidance

• Management expects continued organic growth, especially in Biopharmaceutical Development, and ongoing integration of GKE to expand market reach.

• No material changes to risk factors or forward-looking statements from the prior annual report.